The mission of the ASIP Breast Cancer Scientific Interest Group (SIG) is to advance our understanding of the molecular and cellular pathogenesis of breast cancer enabling the development of new diagnostics and treatments that will lessen the burden of this disease in the United States and world-wide.
The objectives of the ASIP Breast Cancer SIG are:
- To create a community of breast cancer researchers that have a common interest in mechanisms of disease related to breast cancer initiation, progression, and metastasis that are invested in identification of new genes, proteins, and pathways that represent targets for development of new molecular diagnostics, therapeutic strategies, and treatment modalities.
- To promote cutting edge breast cancer research that encompasses basic mechanistic and experimental studies, as well as clinical/translational investigations, and employs state-of-the-art approaches, technologies, methodologies, and model systems.
- To create a conduit for effective outreach to breast cancer researchers (and others with an interest in breast cancer pathobiology) and communication among breast cancer researchers for the dissemination of research news, notification of new research opportunities, and to encourage formation of new multi-disciplinary collaborative teams.
- To engage current predoctoral students and postdoctoral trainees that are interested in breast cancer research, ensuring that a new cadre of experimental pathologists will emerge that are well trained in all aspects of breast cancer pathobiology and well prepared to conduct breast cancer investigations as they transition into research careers.
ASIP Members are invited to participate in the Breast Cancer SIG Listserv. Please email firstname.lastname@example.org to have your name and email address added to the listserv.
To send a message to the Breast Cancer SIG Listserv, send your email to email@example.com. Please note that you must be a member of this listserv to send and receive messages.
William B. Coleman, PhD
American Society for Investigative Pathology
Bethany Hannafon, PhD
University of Oklahoma